Archive for the ‘Conference Coverage with Social Media’ Category

The 14th Annual Personalized Medicine Conference: PREPARING FOR THE NEW POSSIBLE,

November 14, 2018, HMS, Boston


Real Time Press Coverage: Aviva Lev-Ari, PhD, RN



The Infrastructure for Innovation

We need to make the transition to a predict, prevent and protect health system.

Senior Vice President, Global Value, Access and Policy, Amgen

Keynote Speakers

David King, J.D.

Chairman, CEO


Elizabeth Nabel, M.D.


Brigham and Women’s Hospital

Daniel O’Day


Roche Pharmaceuticals


7:00 a.m.
Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.
Opening Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:10 a.m.
Setting the Stage: Exploring the Promise of Personalized Medicine — A Keynote Address

SPEAKER | Elizabeth Nabel, M.D., President, Brigham and Women’s Hospital

8:55 a.m.
Shifting Systems: Identifying the Common Challenges and Notable Achievements of Government Efforts to Advance Personalized Medicine

Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine — but they need to know what works and what doesn’t if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will discuss the competitive advantages various countries have in personalized medicine and explore the common challenges and notable achievements of government initiatives to advance the field during this panel discussion.

MODERATOR Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS European Infrastructure for Translational Medicine

Ora Dar, Ph.D., Senior Expert, Medical Sciences, consultant to the Israel Innovation Authority

Tom Fowler, Ph.D., Deputy Chief Scientist, Genomics England

Marc LePage, President, CEO, Genome Canada

Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland

10:10 a.m.
Networking Break

Light refreshments provided.

10:40 a.m.
Evaluating Patients’ Priorities: Understanding Perspectives on Personalized Medicine — A Fireside Chat

MODERATOR | Susan McClure, Founder, Publisher, Genome magazine; Board Member, Personalized Medicine Coalition

Emily Kramer-Golinkoff, Co-Founder, Emily’s Entourage, cystic fibrosis patient

Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation; stage IV prostate cancer patient

11:10 a.m.
Automating Actionable: How Artificial Intelligence May Chart a Course for Personalized Medicine

Artificial intelligence may help inform personalized medicine in the future by perceiving which genes, proteins and other biological characteristics contribute to human disease. During this session, a diverse panel will discuss how artificial intelligence may accelerate drug development, improve clinical decision support and drive patient outcomes — and what that might mean for the future of health care.

MODERATOR | William S. Dalton, Ph.D., M.D., Founder, Executive Chairman, M2Gen; Board Member, Personalized Medicine Coalition

Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare

Tom Miller, Managing Partner, GreyBird Ventures LLC

Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche

Darrell M. West, Ph.D., Vice President of Governance Studies and Director of Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution

12:25 p.m.
Seated Luncheon
1:40 p.m.
The Lay of the Lab: Exploring the State of the Clinical Laboratory Testing Industry— A Keynote Address

SPEAKER David King, J.D., Chairman, CEO, LabCorp

2:25 p.m.
The Diagnostics Discussion: Evaluating the Extent to Which the Regulatory and Reimbursement Environment for Diagnostic Tests May Help or Hinder Personalized Medicine

The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many observers, however, believe the current regulatory and reimbursement landscape still limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.

MODERATOR Joseph V. Ferrara, CEO, Boston Healthcare Associates

Michael Doherty, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine

Julie Khani, President, American Clinical Laboratory Association

Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

3:25 p.m.
Networking Break

Light refreshments provided.

Sponsored By

3:55 p.m.
Examining Policies: Exploring How Emerging U.S. Regulatory Approaches May Help Facilitate Personalized Care Regimens

The U.S. Food and Drug Administration (FDA) remains firmly committed to regulatory strategies designed to advance personalized medicine. During this wide-ranging fireside chat, two senior leaders from government and industry will discuss the agency’s latest actions impacting the oversight of personalized medicine products and services. The discussion will cover topics including but not limited to next-generation sequencing, diagnostic test regulation, digital health, and real-world evidence.

MODERATOR Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

Jesse Berlin, Sc.D., Vice President and Global Head of Epidemiology, Johnson and Johnson

Lauren Silvis, J.D., Chief of Staff, Immediate Office of the Commissioner, FDA

4:55 p.m.
Engaging Everyone: Leveraging Diversity and Facilitating Equitable Access to Personalized Care

Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease. Also critical is the need to ensure that those patients have access to personalized care informed by those studies. During this session, four panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.

MODERATOR Donna R. Cryer, J.D., President, CEO, Global Liver Institute

Vence L. Bonham, Jr., J.D., Senior Advisor, Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute

Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health

Adolph P. Falcón, Executive Vice President, National Alliance for Hispanic Health

Edward Tepporn, Executive Vice President, Asian & Pacific Islander American Health Forum

5:55 p.m.
Closing Remarks

SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

6:10 p.m.
Departure for the Museum of Fine Arts, Boston
6:30 p.m.
Welcome Reception at the Museum of Fine Arts, Boston

Avenue of the Arts
465 Huntington Avenue
Boston, MA 02115

Sponsored by


Read Full Post »

Live Conference Coverage Medcity Converge 2018 Philadelphia: Clinical Trials and Mega Health Mergers

Reporter: Stephen J. Williams, PhD

1:30 – 2:15 PM Clinical Trials 2.0

The randomized, controlled clinical trial is the gold standard, but it may be time for a new model. How can patient networks and new technology be leveraged to boost clinical trial recruitment and manage clinical trials more efficiently?

Moderator: John Reites, Chief Product Officer, Thread @johnreites
Andrew Chapman M.D., Chief of Cancer Services , Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital
Michelle Longmire, M.D., Founder, Medable @LongmireMD
Sameek Roychowdhury MD, PhD, Medical Oncologist and Researcher, Ohio State University Comprehensive Cancer Center @OSUCCC_James


Michele: Medable is creating a digital surrogate biomarker for short term end result for cardiology clinical trials as well as creating a virtual site clinical trial design (independent of geography)

Sameek:  OSU is developing RNASeq tests for oncogenic fusions that are actionable

John: ability to use various technologies to conduct telehealth and tele-trials.  So why are we talking about Clinical Trials 2.0?

Andrew: We are not meeting many patients needs.  The provider also have a workload that prevents from the efficient running of a clinical trial.

Michele:  Personalized medicine: what is the framework how we conduct clinical trials in this new paradigm?

Sameek: How do we find those rare patients outside of a health network?  A fragmented health system is hurting patient recruitment efforts.

Wout: The Christmas Tree paradigm: collecting data points based on previous studies may lead to unnecessary criteria for patient recruitment

Sameek:  OSU has a cancer network (Orion) that has 95% success rate of recruitment.  Over Orion network sequencing performed at $10,000 per patient, cost reimbursed through network.  Network helps pharma companies find patients and patients to find drugs

Wout: reaching out to different stakeholders

John: what he sees in 2.0 is use of tech.  They took 12 clinic business but they integrated these sites and was able to benefit patient experience… this helped in recruitment into trials.  Now after a patient is recruited, how 2.0 model works?

Sameek:  since we work with pharma companies, what if we bring in patients from all over the US.  how do we continue to take care of them?

Andrew: utilizing a technology is critically important for tele-health to work and for tele-clinical trials to work

Michele:  the utilization of tele-health by patients is rather low.

Wout:  We are looking for insights into the data.  So we are concentrated on collecting the data and not decision trees.

John: What is a barrier to driving Clinical Trial 2.0?

Andrew: The complexity is a barrier to the patient.  Need to show the simplicity of this.  Need to match trials within a system.

Saleem: Data sharing incentives might not be there or the value not recognized by all players.  And it is hard to figure out how to share the data in the most efficient way.

Wout: Key issue when think locally and act globally but healthcare is the inverse of this as there are so many stakeholders but that adoption by all stakeholders take time

Michele: accessibility of healthcare data by patients is revolutionary.  The medical training in US does not train doctors in communicating a value of a trial

John: we are in a value-driven economy.  You have to give alot to get something in this economy. Final comments?

Saleem: we need fundamental research on the validity of clinical trials 2.0.

Wout:  Use tools to mine manually but don’t do everything manually, not underlying tasks

Andrew: Show value to patient

2:20-3:00 PM CONVERGEnce on Steroids: Why Comcast and Independence Blue Cross?

This year has seen a great deal of convergence in health care.  One of the most innovative collaborations announced was that of Cable and Media giant Comcast Corporation and health plan Independence Blue Cross.  This fireside chat will explore what the joint venture is all about, the backstory of how this unlikely partnership came to be, and what it might mean for our industry.

sponsored by Independence Blue Cross @IBX 

Moderator: Tom Olenzak, Managing Director Strategic Innovation Portfolio, Independence Blue Cross @IBX
Marc Siry, VP, Strategic Development, Comcast
Michael Vennera, SVP, Chief Information Officer, Independence Blue Cross

Comcast and Independence Blue Cross Blue Shield are teaming together to form an independent health firm to bring various players in healthcare onto a platform to give people a clear path to manage their healthcare.  Its not just about a payer and information system but an ecosystem within Philadelphia and over the nation.

Michael:  About 2015 at a health innovation conference they came together to produce a demo on how they envision the future of healthcare.

Marc: When we think of a customer we think of the household. So we thought about aggregating services to people in health.  How do people interact with their healthcare system?

What are the risks for bringing this vision to reality?

Michael: Key to experience is how to connect consumer to caregiver.

How do we aggregate the data, and present it in a way to consumer where it is actionable?

How do we help the patient to know where to go next?

Marc: Concept of ubiquity, not just the app, nor asking the provider to ask patient to download the app and use it but use our platform to expand it over all forms of media. They did a study with an insurer with metabolic syndrome and people’s viewing habits.  So when you can combine the expertise of IBX and the scale of a Comcast platform you can provide great amount of usable data.

Michael: Analytics will be a prime importance of the venture.

Tom:  We look at lots of companies that try to pitch technologies but they dont understand healthcare is a human problem not a tech problem.  What have you learned?

Marc: Adoption rate of new tech by doctors is very low as they are very busy.  Understanding the clinicians workflow is important and how to not disrupt their workflow was humbling for us.

Michael:  The speed at which big tech companies can integrate and innovate new technologies is very rapid, something we did not understand.  We want to get this off the ground locally but want to take this solution national and globally.

Marc:  We are not in competition with local startups but we are looking to work with them to build scale and operability so startups need to show how they can scale up.  This joint venture is designed to look at these ideas.  However this will take a while before we open up the ecosystem until we can see how they would add value. There are also challenges with small companies working with large organizations.


Please follow on Twitter using the following #hashtags and @pharma_BI









And at the following handles:




Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center


Read Full Post »

Reporter: Stephen J. Williams, PhD

10:00-10:45 AM The Davids vs. the Cancer Goliath Part 1

Startups from diagnostics, biopharma, medtech, digital health and emerging tech will have 8 minutes to articulate their visions on how they aim to tame the beast.

Start Time End Time Company
10:00 10:08 Belong.Life
10:09 10:17 Care+Wear
10:18 10:26 OncoPower
10:27 10:35 PolyAurum LLC
10:36 10:44 Seeker Health

Karthik Koduru, MD, Co-Founder and Chief Oncologist, OncoPower
Eliran Malki, Co-Founder and CEO, Belong.Life
Chaitenya Razdan, Co-founder and CEO, Care+Wear @_crazdan
Debra Shipley Travers, President & CEO, PolyAurum LLC @polyaurum
Sandra Shpilberg, Founder and CEO, Seeker Health @sandrashpilberg

Belong Life

  • 10,000 cancer patients a month helping patients navigate cancer care with Belong App
  • Belong Eco system includes all their practitioners and using a trigger based content delivery (posts, articles etc)
  • most important taking unstructured health data (images, social activity, patient compilance) and converting to structured data


personally design picc line cover for oncology patients

partners include NBA Major league baseball, Oscar de la Renta,

designs easy access pic line gowns and shirts

OncoPower :Digital Health in a Blockchain Ecosystem

problems associated with patient adherence and developed a product to address this

  1. OncoPower Blockchain: HIPAA compliant using the coin Oncopower security token to incentiavize patients and oncologists to consult with each other or oncologists with tumor boards; this is not an initial coin offering


  • spinout from UPENN; developing a nanoparticle based radiation therapy; glioblastoma muse model showed great response with gold based nanoparticle and radiation
  • they see enhanced tumor penetration, and retention of the gold nanoparticles
  • however most nanoparticles need to be a large size greater than 5 nm to see effect so they used a polymer based particle; see good uptake but excretion past a week so need to re-dose with Au nanoparticles
  • they are looking for capital and expect to start trials in 2020

Seeker Health

  • tying to improve the efficiency of clinical trial enrollment
  • using social networks to find the patients to enroll in clinical trials
  • steps they use 1) find patients on Facebook, Google, Twitter 2) engage patient screen 3) screening at clinical sites
  • Seeker Portal is a patient management system: patients referred to a clinical site now can be tracked

11:00- 11:45 AM Breakout: How to Scale Precision Medicine

The potential for precision medicine is real, but is limited by access to patient datasets. How are government entities, hospitals and startups bringing the promise of precision medicine to the masses of oncology patients

Moderator: Sandeep Burugupalli, Senior Manager, Real World Data Innovation, Pfizer @sandeepburug
Ingo ​Chakravarty, President and CEO, Navican @IngoChakravarty
Eugean Jiwanmall, Senior Research Analyst for Medical Policy & Technology Evaluation , Independence Blue Cross @IBX
Andrew Norden, M.D., Chief Medical Officer, Cota @ANordenMD
Ankur Parikh M.D, Medical Director of Precision Medicine, Cancer Treatment Centers of America @CancerCenter

Ingo: data is not ordered, only half of patients are tracked in some database, reimbursement a challenge

Eugean: identifying mutations as patients getting more comprehensive genomic coverage, clinical trials are expanding more rapidly as seen in 2018 ASCO

Ingo: general principals related to health outcomes or policy or reimbursement.. human studies are paramount but payers may not allowing for general principals (i.e. an Alk mutation in lung cancer and crizotanib treatment may be covered but maybe not for glioblastoma or another cancer containing similar ALK mutation; payers still depend on clinical trial results)

Andrew: using gene panels and NGS but only want to look for actionable targets; they establish an expert panel which reviews these NGS sequence results to determine actionable mutations

Ankur:  they have molecular tumor boards but still if want to prescribe off label and can’t find a clinical trial there is no reimbursement

Andrew: going beyond actionable mutations, although many are doing WES (whole exome sequencing) can we use machine learning to see if there are actionable data from a WES

Ingo: we forget in datasets is that patients have needs today and we need those payment systems and structures today

Eugean: problem is the start from cost (where the cost starts at and was it truly medically necessary)

Norden: there are not enough data sharing to make a decision; an enormous amount of effort to get businesses and technical limitations in data sharing; possibly there are policies needed to be put in place to assimilate datasets and promote collaborations

Ingo: need to take out the middle men between sequencing of patient tumor and treatment decision; middle men are taking out value out of the ‘supply chain’;

Andrew: PATIENTS DON’T OWN their DATA but MOST clinicians agree THEY SHOULD

Ankur: patients are willing to share data but the HIPAA compliance is a barrier


11:50- 12:30 AM Fireside Chat with Michael Pellini, M.D.

Building a Precision Medicine Business from the Ground Up: An Operating and Venture Perspective

Dr. Pellini has spent more than 20 years working on the operating side of four companies, each of which has pushed the boundaries of the standard of care. He will describe his most recent experience at Foundation Medicine, at the forefront of precision medicine, and how that experience can be leveraged on the venture side, where he now evaluates new healthcare technologies.

Michael Pellini, M.D., Managing Partner, Section 32 and Chairman, Foundation Medicine @MichaelPellini

Roche just bought Foundation Medicine for $2.5 billion.  They negotiated over 7 months but aside from critics they felt it was a great deal because it gives them, as a diagnostic venture, the international reach and biotech expertise.  Foundation Medicine offered Roche expertise on the diagnostic space including ability to navigate payers and regulatory aspects of the diagnostic business.  He feels it benefits all aspects of patient care and the work they do with other companies.

Moderatore: Roche is doing multiple deals to ‘own’ a disease state.

Dr. Pellini:  Roche is closing a deal with Flatiron just like how Merck closed deals with genomics companies.  He feels best to build the best company on a stand alone basis and provide for patients, then good things will happen.  However the problem of achieving scale for Precision Medicine is reimbursement by payers.  They still have to keep collecting data and evolving services to suit pharma.  They didn’t know if there model would work but when he met with FDA in 2011 they worked with Precision Medicine, said collect the data and we will keep working with you,

However the payers aren’t contributing to the effort.  They need to assist some of the young companies that can’t raise the billion dollars needed for all the evidence that payers require.  Precision Medicine still have problems, even though they have collected tremendous amounts of data and raised significant money.  From the private payer perspective there is no clear roadmap for success.

They recognized that the payers would be difficult but they had a plan but won’t invest in companies that don’t have a plan for getting reimbursement from payers.

Moderator: What is section 32?

Pellini:  Their investment arm invests in the spectrum of precision healtcare companies including tech companies.  They started with a digital path imaging system that went from looking through a scope and now looking at a monitor with software integrated with medical records. Section 32 has $130 million under management and may go to $400 Million but they want to stay small.

Pellini: we get 4-5 AI pitches a week.

Moderator: Are you interested in companion diagnostics?

Pellini:  There may be 24 expected 2018 drug approvals and 35% of them have a companion diagnostic (CDX) with them.  however going out ten years 70% may have a CDX associated with them.  Payers need to work with companies to figure out how to pay with these CDXs.



Read Full Post »


Live Coverage: MedCity Converge 2018 Philadelphia: AI in Cancer and Keynote Address

Reporter: Stephen J. Williams, PhD

8:30 AM -9:15

Practical Applications of AI in Cancer

We are far from machine learning dictating clinical decision making, but AI has important niche applications in oncology. Hear from a panel of innovative startups and established life science players about how machine learning and AI can transform different aspects in healthcare, be it in patient recruitment, data analysis, drug discovery or care delivery.

Moderator: Ayan Bhattacharya, Advanced Analytics Specialist Leader, Deloitte Consulting LLP
Wout Brusselaers, CEO and Co-Founder, Deep 6 AI @woutbrusselaers ‏
Tufia Haddad, M.D., Chair of Breast Medical Oncology and Department of Oncology Chair of IT, Mayo Clinic
Carla Leibowitz, Head of Corporate Development, Arterys @carlaleibowitz
John Quackenbush, Ph.D., Professor and Director of the Center for Cancer Computational Biology, Dana-Farber Cancer Institute

Ayan: working at IBM and Thompon Rueters with structured datasets and having gone through his own cancer battle, he is now working in healthcare AI which has an unstructured dataset(s)

Carla: collecting medical images over the world, mainly tumor and calculating tumor volumetrics

Tufia: drug resistant breast cancer clinician but interested in AI and healthcareIT at Mayo

John: taking large scale datasets but a machine learning skeptic

moderator: how has imaging evolved?

Carla: ten times images but not ten times radiologists so stressed field needs help with image analysis; they have seen measuring lung tumor volumetrics as a therapeutic diagnostic has worked

moderator: how has AI affected patient recruitment?

Tufia: majority of patients are receiving great care but AI can offer profiles and determine which patients can benefit from tertiary care;

John: 1980 paper on no free lunch theorem; great enthusiasm about optimization algortihisms fell short in application; can extract great information from e.g. images

moderator: how is AI for healthcare delivery working at mayo?

Tufia: for every hour with patient two hours of data mining. for care delivery hope to use the systems to leverage the cognitive systems to do the data mining

John: problem with irreproducible research which makes a poor dataset:  also these care packages are based on population data not personalized datasets; challenges to AI is moving correlation to causation

Carla: algorithisms from on healthcare network is not good enough, Google tried and it failed

John: curation very important; good annotation is needed; needed to go in and develop, with curators, a systematic way to curate medial records; need standardization and reproducibility; applications in radiometrics can be different based on different data collection machines; developed a machine learning model site where investigators can compare models on a hub; also need to communicate with patients on healthcare information and quality information

Ayan: Australia and Canada has done the most concerning AI and lifescience, healthcare space; AI in most cases is cognitive learning: really two types of companies 1) the Microsofts, Googles, and 2) the startups that may be more pure AI


Final Notes: We are at a point where collecting massive amounts of healthcare related data is simple, rapid, and shareable.  However challenges exist in quality of datasets, proper curation and annotation, need for collaboration across all healthcare stakeholders including patients, and dissemination of useful and accurate information


9:15 AM–9:45 AM

Opening Keynote: Dr. Joshua Brody, Medical Oncologist, Mount Sinai Health System

The Promise and Hype of Immunotherapy

Immunotherapy is revolutionizing oncology care across various types of cancers, but it is also necessary to sort the hype from the reality. In his keynote, Dr. Brody will delve into the history of this new therapy mode and how it has transformed the treatment of lymphoma and other diseases. He will address the hype surrounding it, why so many still don’t respond to the treatment regimen and chart the way forward—one that can lead to more elegant immunotherapy combination paths and better outcomes for patients.

Joshua Brody, M.D., Assistant Professor, Mount Sinai School of Medicine @joshuabrodyMD

Director Lymphoma therapy at Mt. Sinai

  • lymphoma a cancer with high PD-L1 expression
  • hodgkin’s lymphoma best responder to PD1 therapy (nivolumab) but hepatic adverse effects
  • CAR-T (chimeric BCR and TCR); a long process which includes apheresis, selection CD3/CD28 cells; viral transfection of the chimeric; purification
  • complete remissions of B cell lymphomas (NCI trial) and long term remissions past 18 months
  • side effects like cytokine release (has been controlled); encephalopathy (he uses a hand writing test to see progression of adverse effect)


  •  teaching the immune cells as PD1 inhibition exhausting T cells so a vaccine boost could be an adjuvant to PD1 or checkpoint therapy
  • using Flt3L primed in-situ vaccine (using a Toll like receptor agonist can recruit the dendritic cells to the tumor and then activation of T cell response);  therefore vaccine does not need to be produced ex vivo; months after the vaccine the tumor still in remission
  • versus rituximab, which can target many healthy B cells this in-situ vaccine strategy is very specific for the tumorigenic B cells
  • HoWEVER they did see resistant tumor cells which did not overexpress PD-L1 but they did discover a novel checkpoint (cannot be disclosed at this point)










Please follow on Twitter using the following #hashtags and @pharma_BI











And at the following handles:




Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

Read Full Post »

Original Tweets Re-Tweets and Likes by @pharma_BI and @AVIVA1950 at #kisymposium for 17th annual Summer Symposium: Breakthrough Cancer Nanotechnologies: Koch Institute, MIT Kresge Auditorium, June 15, 2018, 9AM-4PM


Read Full Post »

SYNOPSIS – 17th annual Summer Symposium: Breakthrough Cancer Nanotechnologies: Koch Institute, MIT Kresge Auditorium, June 15, 2018, 9AM-4PM


Aviva Lev-Ari, PhD, RN,

Founder and Director of LPBI Group will be in attendance covering the event in





All TWEETS from LPBI’s handles at


  • Friday, June 15, 2018
8:00 AM – 9:00 AM Registration/Check-In


9:00 AM – 9:10 AM Introductory Remarks: Tyler Jacks and Sangeeta Bhatia


o   Sangeeta Bhatia,

  • Challenge meet Opportunity – Future Cancer Research Priorities
  • Prevention and early detection of Cancer for improved outcomes
  • Global cancer burden – Cancer diagnosis in Low-resources settings
  • 2000 microchip became nanoscale – other materials in nanoscale: 1994 – Present advancement in material and devices

o   Tyler Jacks

  • Nanotech, Diagnostics, Therapeutics, Cancer Care, Cancer Biology
  • New Center for NanoMedicine @MIT aka, @MIT.NANO
  • Sponsored: J&J, Sanofi, Thermo Scientific


9:10 AM – 10:40 AM Session I: Imaging and Diagnostics

·       Sanjiv Sam Gambhir, MD, PhD, Stanford University

Bubble Based Nanodiagnostics

  • Companies involved: Endra Inc, Bracco, Visualsonics
  • Canary Center Vision: Imaging: identify, isolate, Intervene
  • Value of early cancer detection: Survival is high ONLY in very very early vs tail of the distribution where 90% of funds goes for therapy: Prostate and Breast cancers — ARE detected early
  • Technology: Ultrasound Imaging ($1500 – low cost solution, for molecular level
  • Bubble based Nanodiognostics: Molecular level, gas pore shell made of lipids or albomin – provide information on location of cancer – molecular events, atomical modelity
  • Bubble size nanobubbles vs microbubbles targeted for Vascular Endothilium In vivo
  • Angiogenesis: KDR (molecule)/VEGFR2 (receptor)- over expressed only in neovascularized: Molecular targer is KDR – over expressed in ovarian and breast cancers
  • ability of bubbles to identify cancer, toxicity monitored , bubble arrive, bind, cleared
  • blind to histology – examine the binding, blind pathology
  • bubbles well correlated
  • histological diagnosis few mm to few cm — correlation of lesions benign
  • 1 cm lesion targeted present in KDR, normal tissue clears more rapidly vs in malignant tissue: ductal adenocarcenoma – 11 minutes after injection
  • Duration of US Molecular Imaging Signal
  • First-in-man – Bubble Transrectal US Photoaccustic detection modality
  • Enzyme activation nanobubbles – nano microbubbles to aggregate and create mass impact vs nanobubbles that are weak in signal potential
  • Synthesis of PA/US nanosize RF-acoustic imaging  – target Saline nanodroplets

·       Ralph Weissleder Developing Next Generation Diagnostics for Cancer @MGH

  • translational diagnostics: Precision oncology (1) Imaging (2) Tumor biopsy (3) Liquid biopsy
  • Enable earlier detection
  • Visualization for affordable cost
  • NEW Technologies at MGH with use of AI
  1. Rapid cellular protein profiling – Fine needle aspirates (FNA): DNA Barcode: Epitope – monoclonal antibodies: Sampling, Barcoding, Imaging, Analysis with AI: Pathways in single cells – protein level in different patient:

x axis patient number

y-axis: Protein type

Vesicles from Host vs from Tumor

2, Exosome

surface – Label-free detection and molecualr profiling of exosome : Pancreatic cancer detection – vesicle express  – they are heteroginous micro vesicles

3. POC testing (AI- Defraction Analysis)

Remote diagnosis:

  • Molecular diagnosis – 2015 (PNAS) – nano bids defract patterns – smart phone vs proprietary box – BioMed Eng
  • Algorithms – identify molecules and decision tree Clinical Trial at MGH: 24 Lymphoma patients, rest no-Lymphoma, higher precision than microspectrometry
  • Automated diagnosis – aspirate – subject to dioagnosis in the Box
  • From tissue to single cell
  • multiplex pathways
  • early detection
  • affordability
  • visualization/connectivity for interpretation

·       Angela Belcher New Approaches for Finding Tiny Tumors: Towards Early Detection and Treatment of Ovarian Cancer

  • Nano material and Biomaterial the intersection of
  • Genetic control of materials
  • Carbon nano tubes – Using Bacteriophage or phage – A virus that infect bacteria
  • from DNA to devices
  • Lincoln Labs + MGH + MIT – Carbon Nanotubes used in inexpensive diagnostics: Biomedical imaging: MI, PET: Optical imaging in vivo: Trade-fee: Resolution vs Depth
  • Ovarian Cancer: Minimal increase in overall survival over 30 years : Fallopian tubesmaximum reduction in tumor better survival rate
  • submillimiter detection: Carbon nanotube multiple tubes
  • Pre-surgical planning locates hard-to-detect ovarian tumor – find tumors that are hidden
  • Detection od Optically Luminescent – RT tracking T-cells in Cancer Immmunotherapy – following injection in mice remain for 2 days


·       Angela Belcher,

·       Sanjiv Sam Gambhir,

·       Ralph Weissleder

10:40 AM – 11:00 AM Coffee Break


11:00 AM – 12:30 PM Session II: Therapeutics

·       Mark Davis Designing Nanoparticles to Safely Cross the Blood-Brain Barrier for Treating Brain Cancers

  • Engineer particles for treating solid tumors
  • Intracellular drug delivery
  • 30-50nm
  • Improve PK properties
  • Limit Toxicity
  • Cyclodex
  • Interspecies translation – Nanoparticles can function to design in Humans
  • Combination of Avastin and nanoparticle component
  • PARP Inhibitor + CRLX101 – in clinical trial by AstraZeneka
  • PK in human been presicted if PK known in non-humans
  • Therapeutic escape from the exosome polymer end group chemistry
  • Tumor localization of Nanoparticles
  • Nanoparticles can function in Human NOT in the brain
  • better clinical trial design and combination drugs in small clinical trials
  • Brain primary vs mestasis in th ebrain
  • 50% HER2 positive will have metastesis in the brain
  • BBB TfP Receptor-mediate Transcytosis : Antibody affinity, monodenriate
  • Nanoparticles behave similarity to antibodies in the brain Nanoparticles characteristics: decreased
  • Improved Uptake of Nanoparticles  – fast release of NP during transcytosis
  • bring nanoparticles in combination therapy to the brain using transcytosis

·       Suzie Pun Modulating Tumor-Associated Macrophage

  • TAM – Targeting Tumor-associated macrophages
  • blood monocytes, immunosuppression, metastasis, invasion
  • Can we potentiated therapeutics delivery using TAM
  • wiin tumors, M2pep is internalized by TAMs
  • Cytotoxic KLA peptide – reduce inflammatory of the tumor – M2pepKLA reduces tumor growth rate and improves survival
  • increase avidity binding
  • Immunomodulation – Marophage targeting for
  • Targeting TAM for translation to Humans
  • improve drug potency
  • synthetic Nucleocapsids  —
  • Biomaterials for modulating tumor extracellular matrix
  • FSP integrates into fibrin, increasing its half-life – delay degradation of FSP-fibrin
  • Polymer cross linking – fibrin deposition in brain metastases
  • Fibrin stabilization by FSP alters TAM chronic FSP treatment increases brain metastasis

·       Daniel Anderson Nanoparticle Formulations for RNA Therapy and Gene Editing

  • can we make drugs to repair our DNA for therapy
  • barriers for systemic delivery of nanaoparticles
  • RNA THERAPEUTICS sIRNA – interference: Turning Genes Off: Modular Pharmacology: sequence Selection, Chemical Modification, Encapsulation (like artificial viruses)
  • What material can be used for RNA delivery? – How can we increase diversity?
  • combinatorial synthesis of lipid-like materials
  • RNA Interference – RNA Tx for Liver: Transthyretin-(TTR)
  • TTR in primates, in Humans – Delivery of sRNAi – new class of machines
  • Chylomicron metabolism: The rate of dietary : Mechanism of APoE mediated iLNP delivery
  • sRNAi are not limited for hypatocytes
  • One injection – 5 genes silencing in lung endothelial cells
  • Repaired liver cells in mouth: repopulation of the liver
  • How do we deliver Cas9 in vivo?
  • Modular Pharmacology: Deliver mRNA to inside cells? using nanoparticles
  • chemistry of nanoparticles will delivery to lungs not to liver or to liver not to lungs
  • inhaled nanoparticles for mRNA delivery
  • Cas9 – for gene editing – – Inject AAV-Virus — >> AAV +Cas( mRNA
  • Chemical modification for siRNA: guiding siRNA delivery
  • Guide RNA improve Genome editing
  • Full modification abolishes the function of sgRNA: Cas9-sgRNA
  • e-sgRNA – edited
  • PCKS9- hyperlipidemia — Nanoparticle for in vivo  Genome Editing
  • Delivery to Immune system – Genome editing in vivo of CAR-Ts


·       Daniel Anderson,

·       Mark Davis,

·       Suzie Pun


12:30 PM – 2:00 PM Lunch Break


2:00 PM – 3:00 PM Panel ‘Translation of Nanomedicine to Patients’

Noubar Afeyan, John Maraganore, Bob Langer, Paula Hammond, Michelle Bradbury, Cristianne Rijcken

Moderated by Rebecca Spalding

Noubar Afeyan,

John Maraganore,

Bob Langer,

Paula Hammond,

Michelle Bradbury,

Cristianne Rijcken



3:00 PM – 4:30 PM Session III: Nanosystems and Devices

Sangeeta Bhatia Activity-based biomarkers for non invasive Cancer Detection, Classification and Monitoring

    • Biomarker paradigm for clinical decisions – Endogenous, singular, blood
    • Synthetic Biomarker paradigm for clinical decisions – Exogenous, multiples, urine
    • Endoprotease in Cancer: MMP9, MMP4
    • Synthetic Biomarkers: Sensitivity
    • Enzyme-responsive nanosensors and PK switch [acitvation fluorescence]
    • Benchmarking synthetic biomarkers against a blood biomarker: Urinary synthetic biomarkers outperform CEA
    • multi-compartment modeling for predicting PK
    • Enhancing sensitivity by nanosensor engineering for ovarian cancer detection
    • Mass barcodes enable multiplexing
    • Mass encoded synthetic biomarkers
    • Differentiating similar diseases with protease activity
    • Paper-based microfluidics in urine biomarker
    • synthetic breath biomarkers for lung disease
    • Protease-Responsive Imaging Sensor for Metastasis (PRISM) – localization of Tumor
    • In vivo Enzyme Profiling by Syntahtic Biomarkers

Rashid Bashir Micro and Nanotechnologies for Analysis of Tissues and Molecules

  • liquid biopsy, molecualar analysis of the tumor
  • spatial map of nuclei acids in tissue – Intra tumor heterogeniety
  • subclonal genetic diversity is important
  • laser capture microdissection
  • fluoresence in situ hybridization
  • Cryo-section on microwell array, pixelate and fix tissue inside wells amplification reagents loaded on chip – amplification reaction: Advantages over PCR
  • procees flow on chip
  • On-chip RT-LAMP: Spatial fluorescence analysis
  • ON CHIP RT-LAMP CONTROL: CANCER (red) VS NON-CANCER (blue)  – FTIR control same section
  • Single cell spatial RNA Seq
  • Hematology Analyzer – complete blood celll count  vs FLow cytometry
  • Cells and Proteins from a Drop of Blood

Convergence : The Future of Health – Cancer Center at Illinois

    • Medical Schools MUST Change  CurrentCurriculum vs Future Curriculum
    • NOW: Yr 1: Basic Science Yr 2: Basic Science Yr 3: Clinical Science +  Required rotation Yr 4: Clinical Science +  elective rotation

Jim Heath A Molecular View of Immuno-Oncology, Institute of System Biology

  • Analytical Chemistry challenge:
  • Fundamental Immunology
  • Challenge CRISPR knocking out genes not for knocking in genes
  • Mutated proteins and NEO antiagens: mostly a computational task


·       Rashid Bashir,

·       Sangeeta Bhatia,

·       James Heath

  • Personalized Immuno-Oncology


4:30 PM – 4:50 PM Vladimir Bulović: MIT.nano Nanoscale Discoveries for Transformative Breakthroughs


·       Vladimir Bulović

    • MIT.nano
    • color depend on the size of the molecule
    • Drugs & Vitamins are nano-sized:
    • Scents are nano-sized – a fraction of an atom – ethylene – plant hormone – Pheromones – are nanosized
    • Nanoscale will define many future discoveries
    • 51% of the recently tenured SOS faculty – use nano
    • 67% of the recently tenured SOE faculty with benefits – use nano


4:50 PM – 5:00 PM Closing Remarks


·       Sangeeta Bhatia



Daniel Anderson

Nanoparticle Formulations for RNA Therapy and Gene Editing

Daniel Anderson, PhD
Samuel A. Goldblith Professor of Applied Biology, MIT
Associate Professor, Chemical Engineering and Institute for Medical Engineering and Science, MIT
Member, Koch Institute, MIT

Rashid Bashir

Micro and Nanotechnologies for Analysis of Tissues and Molecules

Rashid Bashir, PhD
Executive Associate Dean and Chief Diversity Officer, Carle Illinois College of Medicine
Grainger Distinguished Chair in Engineering, Professor of Bioengineering, Electrical and Computer Engineering, Mechanical Science and Engineering, Materials Science and Engineering, and Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign

Angela Belcher

New Approaches for Finding Tiny Tumors: Towards Early Detection and Treatment of Ovarian Cancer

Angela Belcher, PhD
James Mason Crafts Professor and Professor of Biological Engineering, MIT
Member, Koch Institute, MIT

Sangeeta Bhatia

Protease Nanosensors for Cancer Detection, Classification and Monitoring

Sangeeta Bhatia, MD, PhD
Director, Marble Center for Cancer Nanomedicine
John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science, MIT
Member, Koch Institute, MIT
Investigator, Howard Hughes Medical Institute

Vladimir Bulović, PhD

Nanoscale Discoveries for Transformative Breakthroughs

Vladimir Bulović, PhD
Director, MIT.nano
Associate Dean for Innovation, MIT School of Engineering
Fariborz Maseeh (1990) Professor of Emerging Technology, Department of Electrical Engineering and Computer Science (EECS), MIT

Mark E. Davis, PhD

Designing Nanoparticles to Safely Cross the Blood-Brain Barrier for Treating Brain Cancers

Mark E. DavisPhD  
Warren and Katharine Schlinger Professor of Chemical Engineering, California Institute of Technology
Member of the City of Hope Comprehensive Cancer Center
Member of the UCLA Jonsson Comprehensive Cancer Center

Sanjiv Sam Gambhir, MD, PhD

Bubble Based Nanodiagnostics

Sanjiv Sam GambhirMD, PhD  
Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research, Professor of Bioengineering, Professor of Materials Science and Engineering, Stanford University

James R. Heath

A Molecular View of Immuno-Oncology

James R. Heath, PhD
President and Professor, Institute for Systems Biology
Professor of Molecular and Medical Pharmacology, UCLA

Suzie H. Pun

Modulating Tumor-Associated Macrophage

Suzie H. Pun, PhD
Robert F. Rushmer Professor of Bioengineering, Adjunct Professor of Chemical Engineering, University of Washington

Ralph Weissleder

Developing Next Generation Diagnostics for Cancer

Ralph Weissleder, MD, PhD
Thrall Professor of Radiology and Professor of Systems Biology, Harvard Medical School
Director of the Center for Systems Biology at Massachusetts General Hospital


Panelists: Translation of Nanomedicine to Patients

Noubar Afeyan

Noubar Afeyan, PhD
Founder and CEO, Flagship Pioneering

Michelle S. Bradbury, MD, PhD

Michelle S. Bradbury, MD, PhD
Co-Director, MSK-Cornell Center for Translation of Cancer Nanomedicines & Director, Intraoperative Imaging Program
Member, Molecular Pharmacology Program, Sloan Kettering Institute
Attending, Radiology, Memorial Sloan Kettering Cancer Center
Professor, Gerstner Sloan Kettering Graduate School of Biomedical Sciences & Weill Medical College of Cornell University

Paula Hammond

Paula Hammond, PhD
Head, Department of Chemical Engineering, MIT
David H. Koch Professor of Engineering, MIT
Member, Koch Institute, MIT

Robert Langer

Robert Langer, ScD
David H. Koch Institute Professor
Member, Koch Institute, MIT

John Maraganore

John Maraganore, PhD
CEO and Director, Alnylam

Cristianne Rijcken

Cristianne Rijcken, PhD
Founder and Chief Scientific Officer, Cristal Therapeutics

Rebecca Spalding


Rebecca Spalding
Biotech Reporter, Bloomberg

Read Full Post »

Reactions to Original Tweets by @Pharma_BI and by @AVIVA1950 from #BIO2018

Curator: Aviva Lev-Ari, PhD, RN


Please review:

  • Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC


  • Original Tweets by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC


  • Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL


     liked a Tweet you were mentioned in

    4h4 hours ago

  1. Gail Thornton Retweeted @pharma_BI

    From Philip K Dick’s obtuse robots to Mark O’Connell’s guide to transhumanism, novelist Julian Gough picks essential reading for a helter skelter world. Can’t wait to read some of the top 10 books. to survive the digital age!

    Gail Thornton added,

     liked your Tweet

    Jun 8

    In case you missed Gail Thornton‘s Tweet

    Jun 8

  2. Gail Thornton Retweeted Aviva Lev-Ari

    Gail Thornton added,

     Retweeted your Tweet

    Jun 8

  3.  liked your Tweets

    Jun 8

    3 other likes

     liked your Tweet

    Jun 7

     liked your Tweet

    Jun 7

     liked your Tweet

    Jun 7

     Retweeted your Tweet

    Jun 7

     liked your Tweet

    Jun 7

  4. Replying to  

    Thanks to Pete Pellerito for keeping the academic zone going . It was great.

     liked your Tweet

    Jun 7

     liked your Tweet

    Jun 7

  5. Replying to   and 2 others


     liked your reply

    Jun 7

     liked your Retweet

    Jun 7

  6.  Retweeted your Retweets

    Jun 6

    10 other Retweets

     Retweeted a Tweet you are mentioned in

    Jun 6

  7.  liked your Tweets

    Jun 6

    2 other likes

  8.  Retweeted your Tweet

    Jun 6

    1 other Retweet

     Retweeted your Tweet

    Jun 6

  9.  liked your Retweets

    Jun 6

    2 other likes

     Retweeted your Retweet

    Jun 6

     and  liked your Tweet

    Jun 6

     and  liked your Tweet

    Jun 6

     and  liked your Tweet

    Jun 6

     liked your Tweet

    Jun 6

     Retweeted your Tweet

    Jun 6

     liked your Tweet

    Jun 6

     liked your Tweet

    Jun 5

     and  liked a Tweet you were mentioned in

    Jun 5

    Recent Tweet from Gail Thornton

    Jun 5

  10. Translate Tweet

  11.  liked Tweets you were included in

    Jun 5

    1 other like

  12.  liked your Tweets

    Jun 5

    7 other likes

     liked your Tweet

    Jun 5

     Retweeted your Tweet

    Jun 4

     Retweeted your reply

    Jun 4

     liked your reply

    Jun 4

     liked your reply

    Jun 4

     liked your reply

    Jun 4

  13.  liked your Tweets

    Jun 4

    1 other like

     liked your Tweet

    Jun 3

Read Full Post »

Older Posts »